All In Biotech

Drug Trial Radar · NCT07594652

Medication Treatment of ADHD in Pediatric Epilepsy

Use of JornayPM® to Treat ADHD in Pediatric Epilepsy

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

May 29, 2026

Primary completion

Dec 2030

Study completion Dec 2030

Sponsor

Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an observational study assessing the usage of stimulant medication for ADHD in the context of pediatric epilepsy.

Conditions

  • ADHD - Attention Deficit Disorder With Hyperactivity

Interventions

  • methylphenidate hydrochloride (Jornay PM)Drug

    all participants will receive active treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Global Impression-ImprovementTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kennedy Krieger Institute

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.